Alzheimer's Disease Clinical Trial
Official title:
Reducing Family Caregiver Upset With Disruptive Behavior
The specific aims of this study are to:
1. Test the immediate effectiveness of the intervention to reduce caregiver upset with
targeted disruptive behaviors (primary outcome). Hypothesis: Caregivers in the
intervention group will report less upset with target behaviors at 4-months in
comparison to caregivers in the control group.
2. Test the immediate effectiveness of the intervention to reduce caregiver burden
(secondary outcome). Hypothesis: Caregivers in the intervention group will report less
burden at 4-months in comparison to caregivers in the control group.
3. Test the immediate effectiveness of the intervention to reduce the frequency of
occurrence of targeted disruptive behaviors in persons with dementia (secondary
outcome). Hypothesis: Caregivers in the intervention group will report a decrease in
the frequency of occurrence of targeted behaviors at 4-months in comparison to
caregivers in the control group.
4. Test the maintenance effect of intervention at 6-months on caregiver upset and burden
and targeted disruptive behaviors. Hypothesis: Compared to usual care, caregivers in
intervention will maintain reduced upset and burden and report less occurrences of
targeted behaviors from 4 to 6-months.
5. Assess the cost of the intervention and its cost effectiveness.
We have also received funding to conduct a supplementary study to evaluate the effect of the
nurse intervention on behavior reduction and caregiver distress. The specific aims of this
supplementary study arm are to: 1) describe the prevalence and type of medical conditions
among control group participants who receive the nurse intervention, 2) describe for those
with a detected medical condition/problem, the number of caregivers who follow-up with
physicians and the type of physician follow-up/treatment that occurs; 3) evaluate whether
control group participants who receive the nurse intervention report reduced disruptive
behaviors and caregiver upset at 6 weeks (pre-post comparison); and 4) for control group
participants who receive the nurse intervention, compare the level of disruptive behaviors
and caregiver upset 4 months from entry into this study arm with the results in the Project
ACT experimental group (who received the multi-component intervention).
n/a
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
| Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
| Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
| Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
| Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
| Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
| Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
| Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
| Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
| Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
| Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
| Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
| Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
| Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
| Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
| Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
| Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
| Completed |
NCT02309723 -
How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints
|
N/A |